IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Transdermal Drug Delivery System

Girish. R. Ghatol[1], Prof. Swapnil. S. Kawarkhe[2], Dr. Swati. P. Deshmukh[3], Akash. G. Tekale [4], Akash. B. Wankhade[5].

1,4,5. Student Shraddha Institute of Pharmacy Kondala Zambre Washim -444505

2. Assistant Professor Department of Pharmacology, Shraddha Institute of Washim

3. Principal of Shraddha Institute of Pharmacy Washim

ABSTRACT

Today about 74% of drugs are taken orally and are found not to be as effective as desired. To improve such character's transdermal drug delivery system was emerged. Drug delivery through the skin to achieve a systemic effect of a drug is commonly known as transdermal drug delivery and differs from traditional topical drug delivery. Transdermal drug delivery systems (TDDS) are dosage forms involves drug transport to viable epidermal and or dermal tissues of the skin for local therapeutic effect while a very major fraction of drug is transported into the systemic blood circulation. The adhesive of the transdermal drug delivery system is critical to the safety, efficacy and quality of the product. Topical administration of therapeutic agents offers many advantages over conventional oral and invasive methods of drug delivery. Several important advantages of transdermal drug delivery are limitation of hepatic first pass metabolism, enhancement of therapeutic efficiency and maintenance of steady plasma level of the drug. This article provides an overview of types of Transdermal patches, methods of preparation and its physicochemical methods of evaluation.

Keywords: Transdermal Patches, TDDS, Matrix, Reservoir, Types of patches

INTRODUCTION

Transdermal delivery may be defined as the delivery of a medicine through 'complete' skin so that it reaches the systemic rotation in sufficient volume, to be salutary after administration of a remedial cure. Transdermal systems are immaculately suited for conditions that demand habitual treatment. Heneman- diabetic agents of both remedial and precautionary operation have been subordinated to transdermal disquisition. Transdermal Drug Delivery System (TDDS) is the advancing area of new medicine delivery, which is designed to transport a therapeutically effective quantum of medicine across a case's skin [1]. The first commercially available TDDS patch of scopolamine was accepted by thus Food and Drug Administration in December 1979 for treatment of stir sickness. The first transdermal patch was approved in 1981 to help the nausea and puking associated with stir sickness. In once 22 times, approx. 35 transdermal patch products, gauging 13 motes 4. Transdermal medicine delivery system was first introduced further than 20 times agone; the technology generated

tremendous excitement and interest amongst major pharmaceutical companies in the 1980s and 90s. Transdermal medicine delivery system (TDDS), also known as "patches," are lozenge forms designed to deliver a therapeutically effective quantum of medicine across a case's skin. Transdermal medicine delivery system has been in actuality for a long time. In the history, the most generally applied systems were topically applied creams and ointments for dermatological diseases. Transdermal delivery not only provides controlled, constant administration of the medicine, but also allows nonstop input of medicines with short natural half- lives and eliminates palpitated entry into systemic rotation, which frequently causes undesirable side effects. Thus, colourful forms of new medicine I delivery system similar as Transdermal medicine delivery systems, Controlled release systems, Transmucosal delivery systems etc. surfaced. Several important advantages of transdermal f medicine delivery are limitation of hepatic first pass metabolism, improvement of remedial effectiveness and conservation of steady tube position of the medicine. Transdermal medicine delivery system has been in actuality for a long time. In the history, the most generally applied systems were topically applied creams and ointments for dermatological diseases. therefore, colourful forms of Novel medicine delivery system similar as Transdermal medicine delivery systems, Controlled Release systems, Transmucosal delivery systems etc. surfaced. Several important advantages of transdermal medicine delivery are limitation of hepatic first pass Metabolism, improvement of remedial effectiveness and conservation of steady tube position of the medicine.

Drug is in direct contact with release liner. Ex Nicotine, Methotrexate and Estrogen. Saturation enhancers Controls the Release of the medicine. Ex Trepans, Dirges, Pyrrolidones. Detergents like alcohol, Ethanol, Methanol. Surfactants like Sodium Laurel sulphate, Plutonic F127, Plutonic F68. Liners Protects the patch during storehouse. Ex polyester film. Adhesive Serves to cleave the patch to the skin for systemic delivery of medicine. Ex Acrylates, Polyisobutylene, Silicones. Saturation enhancers Controls the Release of the medicine. Ex Terpenes, Terpenoids, Pyrrolidone's. Detergents like alcohol, Ethanol, Methanol. Surfactants like Sodium Lauryl sulphate, Pluronic F127, Pluronic F68. Backing subcaste cover patch from external terrain. Ex Cellulose derivations, poly vinyl alcohol, Polypropylene Silicon rubber. Transdermal patch is a treated tenacious patch that's placed on the skin to deliver a specific cure of drug through the skin and into the bloodstream. An advantage of a transdermal medicine delivery route over other types of drug delivery (similar as oral, topical, intravenous, or intramuscular) is that the patch provides



Fig1 Transdermal Patches

APPLICATINS

The loftiest selling transdermal patch in the United States of America is the nicotine patch, which releases nicotine in controlled boluses to help with conclusion of tobacco smoking. The first commercially available vapour patch to reduce smoking was approved in Europe in
2007.

Two opioid specifics used to give round the- timepiece relief for severe pain are frequently specified in patch form, fentanyl CII (retailed as Duragesic) and buprenorphine CIII (retailed as Bitran's).

Hormonal patches:

Estrogen patches are occasionally specified to treat menopausal symptoms (as well as post-menopausal osteoporosis) and to transgender women as a type of hormone relief

Remedy

Contraceptive patches (retailed as Ortho Evra or Evra) and

Testosterone CIII patches for both men (Endoderm) and women (Intrinsic).

Nitro-glycerine patches are occasionally specified for the treatment of angina in lieu of sublingual capsules.

Transdermal scopolamine is generally used as a treatment for stir sickness.

The anti-hypertensive medicine clonidine is available in transdermal patch form.

Emsam, a transdermal form of the MAOI selegiline, came the first transdermal delivery agent for an antidepressant approved for use in the U.S. in March 2006.

Daytrana, the first methylphenidate transdermal delivery system for the treatment of attention deficiency hyperactivity complaint (ADHD), was approved by the FDA in April 2006.

Secuado, a transdermal form of the atypical antipsychotic asenapine, was approved by the FDA in October 2019.

5- Hydroxytryptophan (5- HTP) can also be administered through a transdermal patch, which was launched in the United Kingdom in early 2014.

Rivastigmine, an Alzheimer's treatment drug, was released in patch form in 2007 under the brand name Exelon.

In December 2019, Roberts. Langer and his platoon developed and patented a fashion whereby transdermal patches could be used to label people with unnoticeable essay in order to store medical information subcutaneously.

This was presented as a boon to" developing nations" where lack of structure means an absence of medical records. The technology uses a" amount fleck color that's delivered along with a vaccine".

Caffeine patches, designed to deliver caffeine to the body through the skin.

ADV EVENTS

In 2005, the FDA blazoned that they were probing reports of death and other serious adverse events related to narcotic overdose in cases using Duragesic, the fentanyl transdermal patch for pain control. The Duragesic product marker was latterly streamlined to add safety information in June 2005.

In 2007, Shire and Noven Pharmaceuticals, manufacturers of the DeTrani ADHD patch, blazoned a voluntary recall of several lots of the patch due to problems with separating the patch from its defensive release liner. Since also, no farther problems with either the patch or its defensive packaging have been reported.

In 2008, two manufacturers of the fentanyl patch, ALZA Pharmaceuticals (a division of major medical manufacturer Johnson & Johnson) and Sandoz, latterly issued a recall of their performances of the patch due to a manufacturing disfigurement that allowed the gel containing the drug to blunder out of its poke too snappily, which could affect in overdose and death. As of March 2009, Sandoz — now manufactured by ALZA — no longer uses gel in its transdermal fentanyl patch; rather, Sandoz- ingrained fentanyl patches use a matrix/ glue suspense (where the drug is blended with the tenacious rather of held in a separate Pok with a pervious membrane), analogous to other fentanyl patch manufacturers similar as Mylan and Janssen.

In 2009, the FDA blazoned a public health advisory warning of the threat of becks during MRI reviews from transdermal medicine patches with metallic backings. Cases should be advised to remove any treated patch previous to an MRI checkup and replace it with a new patch after the checkup is complete.

In 2009, a composition in Euro pace journal detailed stories of skin becks that passed with transdermal patches that contain essence (generally as a backing material) caused by shock remedy from external as well as internal cardioverter defibrillators (ICD).

PRINCIPLE

The principle of transdermal drug delivery is to administer medications through the skin, allowing for systemic absorption into the bloodstream. This drug delivery system relies on several key principles:

1. Skin Permeation: The skin serves as a barrier to prevent the entry of foreign substances. Transdermal patches or creams are formulated to penetrate the skin's layers and reach the underlying blood vessels.
2. Controlled Release: Transdermal systems are designed to release drugs at a controlled and consistent rate over an extended period. This ensures a steady concentration of the drug in the bloodstream, minimizing fluctuations.
3. Drug Formulation: Drugs used in transdermal delivery systems are often in a specific formulation that enhances skin penetration. These formulations may include chemical enhancers, permeation enhancers, or prodrugs.
4. Reservoir or Matrix Systems: Transdermal patches typically use either reservoir or matrix systems. Reservoir systems have a drug-containing compartment separated from the skin by a membrane, while matrix systems disperse the drug throughout a polymer matrix. Both allow for controlled drug release.
5. Adhesive Technology: Transdermal patches adhere to the skin to maintain constant contact. They use adhesive materials that are skin-friendly and ensure proper adhesion over the application period.

6. Size and Area: The size and location of the patch on the body can affect drug absorption. Patches are often applied to areas with a good blood supply, such as the upper arm, back, or abdomen.
7. Drug Properties: The drug's physicochemical properties, including molecular weight, lipophilicity, and solubility, influence its ability to penetrate the skin and be delivered via this route.
8. Skin as a Barrier: The skin acts as a protective barrier to the skin as a Barrier: The skin acts as a protective barrier to the external environment. To deliver drugs trans dermally, formulations must penetrate the skin's layers, including the stratum corneum, the outermost layer.
9. Drug Formulation: Drugs for transdermal delivery are typically in the form of patches, gels, creams, or ointments. These formulations contain the active drug and often permeation enhancers to facilitate skin penetration.
10. Permeation Enhancers: Some drugs have difficulty crossing the skin's barrier on their own. Permeation enhancers are added to formulations to improve drug absorption by increasing skin permeability.
11. Sustained Release: Transdermal systems are designed for controlled and sustained drug release over an extended period. This allows for a consistent therapeutic effect and reduces the need for frequent dosing.
12. Patch Application: Transdermal patches are the most common form of transdermal drug delivery. These patches adhere to the skin, and the drug is released slowly over time, absorbing through the skin's layers.
13. Avoidance of First-Pass Metabolism: Transdermal delivery can bypass the liver's first-pass metabolism, which can reduce the risk of drug degradation and enhance bioavailability.
14. Patient Compliance: Transdermal systems are convenient for patients as they eliminate the need for frequent injections or oral dosing, which can improve medication adherence.
15. Monitoring and Safety: Monitoring the release and absorption of the drug is essential to ensure patient safety and efficacy. Transdermal systems can be removed if adverse effects occur.

TYPES OF TRNSDERMAL PATCHES

1. Single subcaste medicine

in tenacious in this type the tenacious subcaste contains the medicine. The tenacious subcaste not only serves to cleave the colourful layers together and also responsible for the releasing the medicine to the skin. The tenacious subcaste is girdled by a temporary liner and a backing. silicon fluid. The rate controlling membrane can be micro pervious or porous polymeric membrane. ethylene vinyl acetate-polymer on the external face of the polymeric membrane, a skin subcaste of medicine, compatible hypo antipathetic tenacious polymer may be applied to achieve an intimate contact of TDDS with skin face. Single subcaste medicine in tenacious type transdermal patch

Fig 2 Single layer drug in adhesive types

2. multi-layer medicine-

in- Adhesive Patches The multi subcaste medicine in glue is analogous to the single subcaste medicine in glue which involves the medicine preface directly into the tenacious subcaste. In this system one of the layers is immediate to release the medicine from the force. This patch also has an endless backing and temporary liner- subcaste. This type is also analogous to the single subcaste but it contains an immediate medicine release subcaste and other subcaste will be a controlled release along with the tenacious subcaste. The tenacious subcaste is responsible for the releasing of the medicine.



Fig 3 Multi-layer Drug in Adhesive Types

3. Reservoir type patches

The force transdermal system has a separate medicine subcaste unlike the single subcaste medicine- in- tenacious and multilayer- medicine- in- guesstimate tenacious element of the product



Fig 4 Reservoir Drug in Adhesive Types

4. Matrix system

a) medicine- in- glue system

In this type the medicine force is formed by dispersing the medicine in a tenacious polymer and also spreading the treated tenacious polymer by solvent casting or melting (in the case of hot- melt bonds) on an impervious backing subcaste. On top of the force, immediate tenacious polymer layers are applied for protection purpose.

b) b) Matrix- dissipation system

In this type the medicine is dispersed homogenously in a hydrophilic or lipophilic polymer matrix. This medicine containing polymer fragment is fixed on to an occlusive base plate in a cube fabricated from medicine an impermeable backing subcaste. rather of applying the glue on the face of the medicine force, it's spread along with the circumference to form a strip of tenacious hem.



Fig 5 Matrix Drug in Adhesive Types

5.Vapour Patch

In this type of patch, the tenacious subcaste not only serves to cleave the colourful layers together but also to release vapour. The vapour patches are new on the request and they release essential canvases for over to 6hours.The vapour patches are new to the request, generally used for releasing of essential canvases in decongestion. colourful other types of vapor patches are also available in the request which are used to ameliorate the quality of sleep and reduces the cigarette smoking conditions.

STATISTICAL USAGE OF TDDS

The usage of transdermal drug delivery system across in India and across the global has been increased due to its safe, efficacious and superb convenience, low rejection rate. It is the most attractive method. Due to its controlled release of drugs, it is widely used. 1.The below is the graphical representation of Global TDD Product sales by segment.

In this we have the highest percentage of Fentanyl i.e., 31% followed by nitro-glycerine (27%), Oestradiol (14%), Nicotine (7%), Clonidine (6%), Testosterone (6%), Tulobuterol (4%), Oestradiol combo (2%) Local pain patches (2%) and the scopolamine has the least percentage i.e., 1%.



Fig 6 Global TDD sale by segment

Conclusion:

This review composition concluded that, an aged medicine by formulating them in new lozenge forms has generated enthusiasm among the pharmaceutical scientists to develop new lozenge forms. In addition, new lozenge forms are essential for other medicines in order to enhance their performance by reducing their cure, adding immersion, delivering to the target point etc. The patented inventions in transdermal medicine delivery arena end at these pretensions. still, the ultimate test that an innovative fashion should pass relates to its successful performance. The development of TDDS technology is extensively honoured as the development of a mass delivery system. which makes it the preferred medicine injection modality for transdermal delivery across skin types, while precluding first- pass metabolism and other sensi- trinities associated with colourful indispensable medicine ad minis traction routes. In colourful bias and TDDSs, medicines can be delivered through the skin to the systemic rotation. medicines are generally reliably and safely delivered through TDDS and are safe and stable.

11. References

1. Jain NK. Advances in controlled and novel drug delivery, 1st Ed., CBS Publishers and distributors, New Delhi, 2001 pp. 108-110.

2. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel. Pharmaceutical dosage forms and drug delivery systems, 8th Edition., Wolter Kluwer Publishers, New Delhi, 2005 pp. 298-299.

3. Chein Y.W. Transdermal drug delivery and delivery system. In, Novel drug delivery system, Vol. 50, Marcel Dekker, Inc., New York, 1992 pp.301-381.

4. Willams A.C and Barry B. W., "Penetration Enhancers," Adv. Drug Del. Rev. 2004;56: 603-618.

5. Pellet M, Raghavan S.L, Had graft J and Davisa. "The application of supersaturated systems to percutaneous drug delivery" In: Guy R.H and Had graft J. Transdermal drug delivery, Marcel Dekker, Inc., New York 2003pp. 305-326.

6. Brown M.B and Jones S.A. Hyaluronic acid: a unique topical vehicle for localized drug delivery of drugs to the skin. JEDV 2000; 19:308-318.

7. Tsai JC, Guy R.H. Thornfeldt C.R. Gown. Feingold K.R and Elias P.M. "Metabolic Approaches to Enhance Transdermal drug delivery". Four-part. Sci., 1998; 85:643-648.

8. Berner B and John V.A. Pharmacokinetic characterization of Transdermal delivery systems. Jour.Clinical pharmacokinetics 1994; 26 (2): 121-34.

9. Baker W and Heller J. "Material Selection for Transdermal Delivery Systems". In Transdermal Drug Delivery: Developmental Issues and ResearchInitiatives, J.Hadgraft and R.H.Guys, Eds. Marcel Dekker, Inc., New york 1989 pp. 293-311.

10. Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. Acta pharm. 1992: 4: 123.

11. Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetes res. Clin. Pract. 1990; 8: 19-22.

12. Al Khamis K, Davis S.S and Hadgraft J. Microviscosity and drug release from topical gel

formulations. Pharm. Res. 1986; 3: 214-217.

13. Anon. Transdermal delivery systems-general drug release standards. Pharmacopeial Forum, 1980, 14: 3860-3865. 14. Mayorga P, Puisieux F and Couarraze G.Formulation study of a Transdermal delivery system of primaquine. Int. J. pharm. 1996; 132: 71-79.

15. Deo M.R, Sant V.P.Parekh S.R, Khopade AJ and Banakar U.V. Proliposome-based Transdermal delivery of levonorgestrel. Jour. Biomat. Appl. 1997; 12: 77-88.

16. Yan-yu X, Yun- mei S, Zhi-Peng C and Qi-nerg P. Preparation of silymarin proliposomes; A new way to increase oral bioavailability of silymarin in beagle dogs. Int. pharm. 2006; 319: 162-168.

17. Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997;60: 312- 314.

18. Singh J, Tripathi K.T and SakiaT.R. Effect of penetration enhancers on the invitro transport of ephedrine through rate skin and human epidermis from matrix based Transdermal formulations. Drug Dev.Ind. Pharm. 1993; 19: 1623-1628.

19. Wade A, Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: Americ Pharmaceutical Publishing Association; 1994: 3 366.

20. Rhaghuram reddy k, Muttalik S and Reddy S. Once daily sustained- release matrix tablets of nicorandil: formulation and invitro evaluation. AAPS Pharm. Sci.Tech. 2003;4:4.

21. Shaila L, Pandey S and Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotin suitable for use in smoking cessation. Indian Journ. Pharm. Sci. 2006;68: 179-184

22. Aarti N, Louk A.R.M.P, Russsel.O.P and Richard H.G. Mechanism of oleic acid induced skin permeation enhancement in vivo in humans. Jour. control. Release 1995; 37: 299-306.

23. Wade A and Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association 1994; 362-366.

24. Lec S.T, Yac S.H, Kim S.W and Berner B. One way membrane for Transdermal drug delivery systems / system optimization. Int. J Pharm. 1991; 77: 231 - 237.

25. Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system1st Ed., CBS Publishers and distributors, New Delhi, 2002; 411- 447.